Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi’s Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya | Zendy

Naftali Busakhala | Zendy; Paul Waako | Zendy; Matthew Strother | Zendy; Alfred Keter | Zendy; Gabriel Kigen | Zendy; Fredrick Chite Asirwa | Zendy; Patrick J. Loehrer | Zendy

Open Access

Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi’s Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya

Author(s) -

Naftali Busakhala,

Paul Waako,

Matthew Strother,

Alfred Keter,

Gabriel Kigen,

Fredrick Chite Asirwa,

Patrick J. Loehrer

Publication year - 2018

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.17.00077

Subject(s) - gemcitabine , medicine , vincristine , adverse effect , oncology , bleomycin , chemotherapy , sarcoma , surgery , cyclophosphamide , pathology

Kaposi's sarcoma (KS) is a spindle cell tumor resulting from growth dysregulation in the setting of infection with human herpes virus-8 (also called KS herpes virus). Advanced KS is characterized by poor responses to antiretroviral therapy and some of the chemotherapy readily accessible to patients in low-resource areas. Gemcitabine induced partial and complete regression of AIDS-associated KS (AIDS-KS) in 11 of 24 patients in a pilot study. The current study compares the antimetabolite gemcitabine with the standard care bleomycin and vincristine (BV) in the treatment of chemotherapy-naïve patients with AIDS-KS in a resource-limited setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research